NuGenesis Technologies of Westborough, Mass., has recently formed two strategic alliances aimed toward expanding its reach in the pharmaceutical industry.
In one partnership, NuGenesis will combine its Scientific Data Management System (SDMS) software with hardware from IBM and Tivoli Systems, an IBM subsidiary. NuGenesis has also forged an alliance with PA Consulting Group of London to provide software consulting services to the pharmaceutical and life science sectors.
The agreements are part of a “discovery initiative” at NuGenesis, said spokeswoman Carolyn Lynch. Until now, NuGenesis has primarily focused on the development and quality assurance/quality control aspects of the pharmaceutical industry.
Under the IBM/Tivoli alliance, users of SDMS, which aggregates disparate types of drug discovery and development data into a common format, will now be able to send output data to the Tivoli Storage Manager backup and archive system. SDMS users will also have access to IBM’s AIX operating system, an open Unix platform for running pharmaceutical applications on enterprise-class servers.
Lynch said the IBM partnership is “part one of an ongoing relationship with IBM, in light of how they have this life sciences initiative and that fits right into our scope.”
Anne-Marie Derouault, director of business development for IBM Life Sciences, said, “NuGenesis’ support for IBM and Tivoli systems is further validation of IBM’s growing leadership as an IT provider to the life sciences industry.”
In the PA alliance, NuGenesis and PA intend to jointly help companies implement software tools throughout the data integration and drug discovery processes.
“PA enables us to widen our scope through their innovative and pragmatic approach to improve and shorten development time scales,” said Michael McGuinness, president of NuGenesis.
IBM recently announced its own plans to offer a software consulting service for its partners in biotech and pharmaceutical companies through its Global Services unit.
IBM and NuGenesis/PA join several smaller companies such as Blackstone Technology Group and 3 rd Millennium who have built businesses around offering hardware and software consulting services to genomics companies.
“IBM is already in at a lot of these pharmaceutical companies as their hardware platform and they’re trying to get into life sciences, as we are already, so there’s a mutual initiative between both of us that we are targeting the same group,” said Lynch.
The two companies are selling the combined platform under an independent revenue scheme, although Lynch said the exact terms were still being worked out.
Lynch added that NuGenesis is currently in late-stage development for global deployment of the combined NuGenesis/Tivoli platform with two large pharmaceutical companies.